Hong Kong, July 30, 2026 (GLOBE NEWSWIRE) — INNO HOLDINGS INC. (Nasdaq: INHD) (“INNO” or the “Company”), a Texas holding company, today announced that its common stock will resume trading on The Nasdaq Capital Market. As previously disclosed in a Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on June 12, 2026, The Nasdaq Stock Market LLC imposed a trading halt under Code T12 on the trading of the Company’s common stock. The trading halt is being lifted and, as a result, trading of the Company’s common stock is expected to resume on The Nasdaq Capital Market at or around noon, eastern time on July 31, 2026, rather than at the opening of trading as previously announced. The Company is not aware of any material, undisclosed corporate developments that would account for the unusual trading activities...

MELBOURNE, Australia and INDIANAPOLIS, July 31, 2026 (GLOBE NEWSWIRE) — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today advises that it will release its financial results for the half-year ended June 30, 2026 on Thursday August 20, 2026. An investor webcast and conference call will be held at 9:00 a.m. AEST on Thursday August 20, 2026 (7:00 p.m. EDT Wednesday August 19, 2026). Participants can register for the webcast or teleconference at the following link: https://s1.c-conf.com/diamondpass/10056417-pz2402.html About Telix Pharmaceuticals Limited Telix Pharmaceuticals (ASX: TLX, NASDAQ: TLX) is a commercial-stage global radiopharmaceutical company, advancing targeted theranostics to improve outcomes for people with cancer across the patient journey. Theranostics pairs a precision diagnostic with a targeted...

Advisory Committee voted 10 to 3 that the efficacy results from the IGNYTE study are evaluable and clinically meaningful WOBURN, Mass., July 30, 2026 (GLOBE NEWSWIRE) — Replimune Group, Inc. (Nasdaq: REPL), a clinical-stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced the outcome of today’s meeting of the U.S. Food and Drug Administration’s (FDA) Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC), which discussed the Biologics License Application (BLA) resubmission for RP1 (vusolimogene oderparepvec) in combination with nivolumab for the treatment of advanced melanoma in patients who have progressed on prior anti-PD-1 therapy. The committee discussed two topics: (1) whether the single-arm IGNYTE study, as designed and conducted, allows for a reliable...

No Stockholder Action Required at This Time REDWOOD CITY, Calif., July 30, 2026 (GLOBE NEWSWIRE) — Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today confirmed that on July 28, 2026, it received a further revised, unsolicited, non-binding acquisition proposal from Bradley L. Radoff and Michael Torok (together with certain of their affiliates, the “Radoff-JEC Group”) to acquire all of the outstanding shares of Seer’s Class A common stock for $2.55 per share in cash plus a contingent value right. On July 29, 2026, Seer received a revised, unsolicited, non-binding acquisition proposal from Omid Farokhzad, M.D., Seer’s Chair and Chief Executive Officer, to acquire all of the outstanding shares of Seer’s Class A common stock for $2.45 per share in cash plus two separate contingent...

MONTREAL, July 30, 2026 (GLOBE NEWSWIRE) — Prime Drink Group Corp. (CSE: PRME) (“Prime” or the “Company) announces that further to its press release dated June 12, 2026, it has extended its previously announced non-brokered private placement offering of units of the Company (the “Units”) to raise minimum gross proceeds of $1,200,000 and maximum gross proceeds of $2,200,000 (the “Unit Offering”). The Unit Offering is expected to close on or by September 14, 2026. Each Unit will be offered at a price of $10,000 per Unit and is comprised of 200,000 common shares in the capital of the Company (the “Common Shares”) and 200,000 transferable share purchase warrants (the “Warrants”), resulting in the aggregate issuance of a minimum of 24,000,000 Common Shares and of a maximum of 44,000,000 Common Shares issued at a deemed price per share...

Châtillon, France, July 30, 2026 DBV Technologies Announces Sale of Approximately $50 Million of ADSs Through Its At-The-Market (ATM) Program on Nasdaq DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Capital Market: DBVT) (the “Company”), a late-stage biopharmaceutical company, today announced that, pursuant to the Company’s At-The-Market Program established on September 1, 2025 and included in a new registration statement and accompanying prospectus filed on July 27, 2026, (the “ATM Program”), it has agreed to issue and sell new ordinary shares (the “Ordinary Shares”) in the form of American Depositary Shares (“ADSs”), for total gross proceeds to the Company of approximately $50 million, before deducting sales agent commissions and offering expenses payable by the Company, to RA Capital Management, L.P (“RA Capital”) through...

LOS ANGELES, July 30, 2026 (GLOBE NEWSWIRE) — Xos, Inc. (NASDAQ: XOS), a leading electric truck manufacturer and fleet services provider, today announced it will release its second quarter ended June 30, 2026 operating results on Thursday, August 13, 2026, after the close of the U.S. financial markets. Management will host a conference call and webcast to discuss these financial results at 4:30 p.m. Eastern Daylight Time / 1:30 p.m. Pacific Daylight Time on August 13, 2026. Conference Call and Webcast DetailsDate / Time: Thursday, August 13, 2026, at 4:30 p.m. EDT / 1:30 p.m. PDTWebcast: https://viavid.webcasts.com/starthere.jsp?ei=1770255&tp_key=a5f3b5b3ecU.S. Toll-Free Dial In: 1-833-816-1411International Dial In: 1-412-317-0507Conference ID: 10210727   To access the call, please dial in approximately...

NEW YORK, July 30, 2026 (GLOBE NEWSWIRE) — Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the second quarter 2026 ending June 30, 2026 on Thursday, August 6, 2026 after the close of the US market. The press release will be available in the Investors section of Cellectis’ website: https://www.cellectis.com/en/investors/press-releases/ Cellectis will not host a conference call to discuss these results. Our investor relations team remains available for questions at investors@cellectis.com About Cellectis Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and...